Cervical Total Disc Replacement Device Market, By Material (Metal-on-metal and Metal-on-biocompatible), By Design (Constrained, Semi-constrained, and Unconstrained), By End User (Hospitals, Ambulatory Surgical Center and Specialty Clinics, and Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023

Code : CMI1763

Pages :160

Formats :

Excel and PDF

Industry : Medical Devices

Regional Analysis

Global Cervical Total Disc Replacement Device Market- Regional Analysis

Among regions, North America is expected to hold a dominant position in the global cervical total disc replacement device market over the forecast period. North America is estimated to hold 41.1% market share in 2023 due to the increasing adoption of organic growth strategies such as pre-market approval, which is expected to propel the market growth during the forecast period. For instance, in March 2019, MCRA, LLC, one of the leading adviser and clinical research organizations to the neuro-musculoskeletal and orthopedic industry, announced its role in the successful Premarket Approval (PMA) application decision by the U.S. Food and Drug Administration (FDA) to approve Orthofix M6-C artificial cervical disc for the treatment of single-level cervical disc degeneration. M6-C disc, a next-generation artificial cervical disc created by Spinal Kinetics LLC, is the only artificial cervical disc intended to closely resemble a natural disc's anatomical structure. MCRA was first hired by Spinal Kinetics, a medical company using Board Certified Radiologists use CRMA (radiographic mensuration criteria in 2008 during the preliminary phases of creating the clinical research approach for M6-C artificial cervical disc, which was later bought by Orthofix Medical Inc. one of the leading medical device company and provider of spinal, orthopedic, bone growth, and motion preservation products in 2018. It took 15 months for the FDA to analyze and approve the PMA for the M6-C disc after it was submitted on February 6, 2019. Furthermore, M6-C artificial cervical disc's PMA certification is the first original PMA approval for a spinal device since 2015.

Moreover, research and development of cervical total disc replacement technology is expected to offer lucrative growth opportunities to market players in Europe. For instance, in September 2019, researchers from the Institute for Biomechanics, Switzerland reported the development of a method for controlled epigallocatechin 3-gallate delivery in the degeneration of the intervertebral disc. The approach is expected to restore the homeostasis of the degeneration of the intervertebral disc. Moreover, the availability of CE marked products such as Freedom Cervical Disc developed by AxioMed LLC, a company focused on developing first-generation artificial discs in the region is contributing to the Europe cervical total disc replacement device market growth.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa